---
run_id: halo-evidence-vs-diagnosis-validation-v12-famous-sources-supplied-02
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: famous_sources_supplied
run_number: 2
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 202
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no benefits cases, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: fbda9621700ea5a031af698b8700a95ac925370d84a60c86c1d7bce543e8cc3b
condition_packet_sha256: fbda9621700ea5a031af698b8700a95ac925370d84a60c86c1d7bce543e8cc3b
output_file: model-outputs/famous_sources_supplied-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `famous_sources_supplied`, run 2 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 202, on the frozen condition packet.

## Output

**Recommendation:** Run the **Case Evidence Review**.

**Why:**
The company is currently experiencing a "Halo Effect" (per Rosenzweig), where strong financial metrics—driven by temporary pricing bundles and sales optimism—are masking fundamental product-market fit issues. The current data is "entangled": usage is high, but the *nature* of that usage (managers rerunning samples for meetings) does not indicate value creation for the primary user.

The Case Evidence Review is the only proposed option that addresses the "Jobs to be Done" (per Christensen) for the front-line analyst. The evidence suggests a critical failure in "explainability" (especially in public sector) and a regression to manual notes. Without knowing *why* suggestions are overridden or impossible to explain, scaling the product is a risk, and the Adoption Quality Sprint (which measures *if* they return) will not explain *why* they are failing. The Demand Cleanroom measures sales appetite, but the current data suggests that while buyers *want* the vision, users are struggling with the utility. You must validate the core value proposition at the workflow level before committing next year's budget to scaling.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation tests. Unlike the Adoption Quality Sprint (which relies on automated event tracking) or the Demand Cleanroom (which relies on sales outcomes), a Case Evidence Review requires manual, qualitative analysis of files and interviews. In a twelve-day window before the board locks the budget, this method provides the least "instant" quantitative gratification for an executive team currently riding a wave of expansion bookings.

**Observable evidence that would change my mind:**
If the "Demand Cleanroom" were to reveal that buyers are willing to pay a significant premium for PlanPilot *specifically* because it solves the "explainability" problem for their internal reviewers (meaning the value is perceived as a compliance/audit tool rather than a productivity tool), I would pivot to scaling the product. If the demand is driven by the *existence* of an automated plan rather than the *accuracy* or *utility* of that plan, the product risk is lower and the commercial opportunity takes precedence.
